3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Sunitinib
17
Sorafenib
16
pazopanib
7
cabozantinib
7
Axitinib
7
Blood Specimen Collection
6
Bevacizumab
6
avelumab
5
Immunohistochemistry
5
temsirolimus
4
pembrolizumab
3
Watchful Waiting
3
Specimen Handling
3
Immunotherapy
3
Gene Expression Profiling
3
Everolimus
3
Urine Specimen Collection
2
Nephrectomy
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Flow Cytometry
2
Data Collection
2
Amplified Fragment Length Polymorphism Analysis
2
trastuzumab deruxtecan
1
lenvatinib
1
fluoroazomycin arabinoside
1
enfortumab vedotin
1
darolutamide
1
atezolizumab
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Carcinoma, Renal Cell
×
Blood Component Removal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled